Does Bijuva (conjugated estrogens and bazedoxifene) cause fatigue or sedation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Bijuva Does Not Cause Fatigue or Sedation

Based on available evidence, Bijuva (17β-estradiol/progesterone) is not associated with fatigue or sedation as adverse effects. The clinical trial data and FDA approval documentation for this bioidentical hormone product do not list fatigue or sedation among reported side effects.

Evidence from Clinical Trials

The phase 3 clinical study that led to Bijuva's FDA approval evaluated its safety profile over 52 weeks in postmenopausal women with an intact uterus 1. The study focused on:

  • Reduction in frequency and severity of vasomotor symptoms
  • Endometrial safety (no cases of endometrial hyperplasia observed)
  • Common adverse effects

The documented adverse effects did not include fatigue or sedation. This is an important distinction when counseling patients about what to expect from this medication.

Distinguishing Bijuva from Duavee

It's critical to note that Bijuva is NOT the same as Duavee (conjugated estrogens/bazedoxifene), which is what most of the provided evidence discusses. These are two distinct products:

  • Bijuva: 17β-estradiol 1 mg + progesterone 100 mg (bioidentical hormones)
  • Duavee: Conjugated estrogens 0.45 mg + bazedoxifene 20 mg (SERM-based combination)

What About Duavee's Side Effect Profile?

While the question asks about Bijuva, the evidence provided primarily addresses Duavee. For completeness, Duavee's documented side effects include 2:

  • Muscle spasms
  • Nausea, diarrhea, dyspepsia, upper abdominal pain
  • Throat pain
  • Dizziness
  • Neck pain
  • Hot flushes and leg cramps (similar to other SERMs)

Notably, fatigue and sedation are not listed among Duavee's adverse effects either.

Clinical Context: Sleep Improvements vs. Sedation

Interestingly, studies of conjugated estrogens/bazedoxifene actually showed improvements in sleep parameters rather than sedation 2, 3. At 12 months, patients demonstrated:

  • Improved time to fall asleep
  • Reduced sleep disturbance
  • Better sleep adequacy
  • Enhanced sleep problem indices

These improvements reflect better sleep quality from relief of menopausal symptoms (particularly hot flashes), not sedative effects of the medication itself.

Important Counseling Points

When discussing Bijuva with patients:

  • Do not expect sedation or fatigue as medication effects
  • If fatigue develops, investigate other causes (thyroid dysfunction, anemia, depression, sleep disorders)
  • The medication is taken once daily as an oral capsule
  • Common side effects are typically related to hormonal effects, not central nervous system depression

Clinical Pitfall to Avoid

Do not confuse patient reports of "feeling tired from hot flashes" with medication-induced fatigue. The goal of Bijuva is to reduce fatigue associated with menopausal symptoms by treating the underlying vasomotor symptoms that disrupt sleep and quality of life 1.

References

2
Guideline

american association of clinical endocrinologists/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2020

Related Questions

Is a fixed‑dose combination of bazedoxifene (20 mg) with conjugated estrogens (0.45 mg) appropriate for a post‑menopausal woman with vasomotor symptoms and osteoporosis (lumbar T‑score –3) and no prior fractures?
What is the recommended dosing regimen for Bi‑Est cream (80 mg estradiol + 20 mg progesterone per gram) in post‑menopausal women?
Can eatragyn be used as a substitute for Premarin (conjugated equine estrogens) when Premarin is unavailable due to manufacturer shortages?
Can bazedoxifene (Slinda) be used for endometrial protection in a postmenopausal woman with an intact uterus who is receiving estrogen-only hormone replacement therapy?
Is the compounded Bi‑Est 80:20 vaginal cream containing 0.5 mg estriol/estradiol and 10 mg micronized progesterone applied daily appropriate for a post‑menopausal woman with a uterus, and what evidence‑based regimen should be used instead?
What is the recommended starting dose and titration schedule for tamsulosin, and how should it be monitored for efficacy and side effects?
What do elevated ALT, lymphocytosis, monocytosis, neutrophilia, thrombocytosis, low MCHC, low total bilirubin, and leukocytosis suggest?
In patients with chronic kidney disease who have hypertension or albuminuria, how should ACE inhibitors be initiated, dosed, monitored, and what are the contraindications and alternatives?
Are there any drug interactions between desmopressin and ibandronate?
What alternative psychiatric approach can be used instead of a psychoeducational approach?
What findings on a complete blood count indicate an infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.